The response to activated protein C after cardiopulmonary bypass: Impact of factor V Leiden

Anesthesia and Analgesia

Volumn 99, Issue 6, 2004, Pages 1598-1603

  Donahue, Brian S ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; CARRIER PROTEIN; PROTAMINE;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; DISEASE ASSOCIATION; HEART SURGERY; HETEROZYGOTE DETECTION; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; PLASMA; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS; TREATMENT OUTCOME;

ACTIVATED PROTEIN C RESISTANCE; CARDIOPULMONARY BYPASS; DNA; FACTOR V; FEMALE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROTEIN C; THROMBOPHILIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 9244259711     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000136424.91661.E4     Document Type: Article

References (38)

1. Milas BL, Jobes DR, Gorman RC. Management of bleeding and coagulopathy after heart surgery. Semin Thorac Cardiovasc Surg 2000;12:326-36.
2. Koh MB, Hunt BJ. The management of perioperative bleeding. Blood Rev 2003;17:179-85.
3. Hogue CW Jr, Murphy SF, Schechtman KB, Davila-Roman VG. Risk factors for early or delayed stroke after cardiac surgery. Circulation 1999;100:642-7.
4. Hogue CW Jr, Sundt T 3rd, Barzilai B, et al. Cardiac and neurologic complications identify risks for mortality for both men and women undergoing coronary artery bypass graft surgery. Anesthesiology 2001;95:1074-8.
5. Spiess BD. Ischemia: a coagulation problem? J Cardiovasc Pharmacol 1996;27(Suppl 1):S38-41.
6. Raymond PD, Marsh NA. Alterations to haemostasis following cardiopulmonary bypass and the relationship of these changes to neurocognitive morbidity. Blood Coagul Fibrinolysis 2001;12:601-18.
7. Jain U. Myocardial ischemia after cardiopulmonary bypass. J Card Surg 1995;10:520-6.
8. Hill GE. Cardiopulmonary bypass-induced inflammation: is it important? J Cardiothorac Vasc Anesth 1998;12:21-5.
9. Jaggers JJ, Neal MC, Smith PK, et al. Infant cardiopulmonary bypass: a procoagulant state. Ann Thorac Surg 1999;68:513-20.
10. Hill GE. The inflammatory response to cardiopulmonary bypass. Int Anesthesiol Clin 1996;34:95-108.
11. Nannizzi-Alaimo L, Rubenstein MH, Alves VL, et al. Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation 2002;105:2849-54.
12. Hyde JA, Chinn JA, Graham TR. Platelets and cardiopulmonary bypass. Perfusion 1998;13:389-407.
13. Ziegeler S, Tsusaki BE, Collard CD. Influence of genotype on perioperative risk and outcome. Anesthesiology 2003;99:212-9.
14. Esmon CT. The protein C pathway. Chest 2003;124:26S-32.
15. Clark P, Walker ID. The phenomenon known as acquired activated protein C resistance. Br J Haematol 2001;115:767-73.
16. Spronk HM, Govers-Riemslag JW, ten Cate H. The blood coagulation system as a molecular machine. Bioessays 2003;25:1220-8.
17. Bernardi F, Faioni EM, Castoldi E, et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997;90:1552-7.
18. Clark P, Brennand J, Conkie JA, et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998;79:1166-70.
19. Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost 2003;29:125-30.
20. Sweeney JD, Blair AJ, Dupuis MP, et al. Aprotinin, cardiac surgery, and factor V Leiden. Transfusion 1997;37:1173-8.
21. Williamson D, Brown K, Luddington R, et al. Factor V Cambridge: a new mutation (Arg306->Thr) associated with resistance to activated protein C. Blood 1998;91:1140-4.
22. Bajzar L, Kalafatis M, Simioni P, Tracy PB. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden. J Biol Chem 1996;271:22949-52.
23. Nicolaes GA, Dahlback B. Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler Thromb Vasc Biol 2002;22:530-8.
24. Petaja J, Pesonen E, Fernandez JA, et al. Cardiopulmonary bypass and activation of antithrombotic plasma protein C. J Thorac Cardiovasc Surg 1999;118:422-9; discussion 429-31.
25. Moor E, Silveira A, van't Hooft F, et al. Coagulation factor V (Arg506->Gln) mutation and early saphenous vein graft occlusion after coronary artery bypass grafting. Thromb Haemost 1998;80:220-4.
26. Donahue BS, Gailani D, Higgins MS, et al. Factor V Leiden protects against blood loss and transfusion after cardiac surgery. Circulation 2003;107:1003-8.
27. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and Venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-7.
28. Van Cott EM, Soderberg BL, Laposata M. Activated protein C resistance, the factor V Leiden mutation, and a laboratory testing algorithm. Arch Pathol Lab Med 2002;126:577-82.
29. De Stefano V, Chiusolo P, Paciaroni K, Leone G. Epidemiology of factor V Leiden: clinical implications. Semin Thromb Hemost 1998;24:367-79.
30. Esmon CT. Protein C pathway in sepsis. Ann Med 2002;34:598-605.
31. Cheng T, Liu D, Griffin JH, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003;9:338-42.
32. Gelb AB, Roth RI, Levin J, et al. Changes in blood coagulation during and following cardiopulmonary bypass: lack of correlation with clinical bleeding. Am J Clin Pathol 1996;106:87-99.
33. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995;74:449-53.
34. Zoller B, Garcia de Frutos P, Hillarp A, Dahlback B. Thrombophilia as a multigenic disease. Haematologica 1999;84:59-70.
35. Kiechl S, Muigg A, Santer P, et al. Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. Circulation 1999;99:614-9.
36. Kim AY, Walinsky PL, Kolodgie FD, et al. Early loss of thrombomodulin expression impairs vein graft thromboresistance: implications for vein graft failure. Circ Res 2002;90:205-12.
37. Petaja J, Lundstrom U, Sairanen H, et al. Central venous thrombosis after cardiac operations in children. J Thorac Cardiovasc Surg 1996;112:883-9.
38. Ong BC, Zimmerman AA, Zappulla DC, et al. Prevalence of factor V Leiden in a population of patients with congenital heart disease. Can J Anaesth 1998;45:1176-80.